Biofabri, S.L   Report issue

For profit Phase 2 Phase 3
Founded: Pontevedra Spain (2008)

Organization Overview

First Clinical Trial
2013
NCT02013245
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Biofabri, S.L

Active Ingredients

Drugs in Phase 3 Trials (2)

bacille calmette-guerin (3 trials)

mtbvac (5 trials)

Drugs in Phase 2 Trials (3)

Measles, Mumps and Rubella Vaccine, Live (Priorix) (1 trial)

mv-chik (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chikungunya Fever (Phase 2)

Latent Tuberculosis (Phase 2)

Tuberculosis (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5